Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun:173:105271.
doi: 10.1016/j.rvsc.2024.105271. Epub 2024 Apr 14.

Safety of an oral combination of moxidectin, afoxolaner, and pyrantel pamoate in dogs

Marlene Drag  1 , Eric Tielemans  2 , Elizabeth Mitchell  3 , John W McCall  4 , Norba Targa  3 , Richard Bruner  5 , Stephen Yoon  3 , Beth Colley  1 , Becky Fankhauser  3
Affiliations
Free article

Safety of an oral combination of moxidectin, afoxolaner, and pyrantel pamoate in dogs

Marlene Drag et al. Res Vet Sci. 2024 Jun.
Free article

Abstract

NexGard®PLUS (moxidectin, afoxolaner, and pyrantel pamoate), is an oral combination product for dogs indicated for the prevention of heartworm disease, the treatment and prevention of flea and tick infestations, and the treatment of gastro-intestinal nematode infections. The safety of this product in dogs was evaluated in three studies. Study #1 was a margin-of-safety study conducted in puppies, dosed six times at 28-day intervals at 1X, 3X, or 5X multiples of the maximum exposure dose (equivalent to 24 μg/kg moxidectin, 5 mg/kg afoxolaner, and 10 mg/kg pyrantel). In Study #2, the product was administered to ABCB1-deficient collie dogs at a 1X dose twice at a 28-day interval, and at a 3X or 5X dose once. Study #3 evaluated the safety of the product at 1X and 3X doses administered three times at 4-week intervals, to dogs harboring adult Dirofilaria immitis. In the three studies, the safety was evaluated on the basis of multiple clinical observations and physical examinations, including a complete assessment of toxicity to macrocyclic lactones, and on comprehensive clinical and anatomical pathology evaluations in Study #1. No clinically significant combination product-related effects were observed in any of the three studies. No signs of macrocyclic lactone toxicity were observed in the ABCB1-deficient collie dogs. Some mild and self-resolving instances of emesis or diarrhea were occasionally observed in the 3X and 5X dosed dogs. NexGard® PLUS was demonstrated to be safe following multiple administrations in puppies, in ABCB1-deficient collie dogs, and in microfilaremic dogs infected with adult D. immitis.

Keywords: ABCB1-deficient; Afoxolaner; Dog; Heartworm positive; Moxidectin; Safety.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The work reported herein was funded by Boehringer Ingelheim. Some of the authors are former or current employees of Boehringer Ingelheim. Other than that, the authors declare no conflict of interest. This document is provided for scientific purposes only. Any reference to a brand or trademark herein is for information purposes only and is not intended for any commercial purposes or to dilute the rights of the respective owners of the brand(s) or trademark(s). NexGard® is a registered trademark of the Boehringer Ingelheim group. The work reported herein was funded by Boehringer-Ingelheim. Some of the authors are current or former employees of Boehringer-Ingelheim Animal Health. This document is provided for scientific purposes only. Any reference to a brand or trademark herein is for information purposes only and is not intended for any commercial purposes or to dilute the rights of the respective owners of the brand(s) or trademark(s). NexGard PLUS® is a registered trademark of Boehringer Ingelheim Animal Health.

Similar articles

See all similar articles

LinkOut - more resources